Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249554 | 0.82 | CA2 (0.63) | CA2CA1MMP2MMP9ADAM17 | |
| SCHEMBL2246525 | 0.81 | NPC1 (0.43) | CA2CA1SMN1; SMN2 | |
| SCHEMBL7047276 | 0.75 | CTSL (0.49) | CA2CA1SMN1; SMN2BCHEACHE | |
| SCHEMBL2249549 | 0.75 | MMP12 (0.60) | CA2CA1MMP2MMP9ADAM17 | |
| SCHEMBL4623715 | 0.74 | GPR132 (0.53) | SMN1; SMN2ERCC5FEN1 | |
| SCHEMBL7046034 | 0.73 | CA2 (0.53) | CA2CA1 | |
| SCHEMBL5999343 | 0.73 | MMP2 (0.52) | MMP2MMP9ADAM17SMN1; SMN2MMP12 | |
| SCHEMBL7046023 | 0.73 | ACE (0.60) | CA2CA1SMN1; SMN2 | |
| SCHEMBL2247834 | 0.72 | CYP26A1 (0.47) | CA2CA1MMP2MMP9SMN1; SMN2 | |
| SCHEMBL2247559 | 0.72 | ALDH1A1 (0.58) | CA2CA1SMN1; SMN2ERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | CA2 134/4885CA1 65/4885MMP2 49/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | CA2 134/4885CA1 65/4885MMP2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.